Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    18753647 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Withdrawn Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
2 Completed VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: bortezomib

Indicates status has not been verified in more than two years